Baxter International Inc (BAX) stock

BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/304% above fair value

$25.81+0.07 (+0.27%)

Close on Nov 13, 2026Market cap $13.35BP/E –Yield 2.01%

Baxter International statistics

90 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Feb 11, 2027 (estimated, before the open)
Last ex-dividend date: Aug 28, 2026
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $13.35B; $498.53M
Enterprise Value: $12.19B; $433.11M
PS Ratio: 1.15; 2.94
PB Ratio: 2.05; 3.24
P/OCF Ratio: 8.14; 21.97

Enterprise valuationIndustry

EV / Sales: 1.05; 2.60
EV / EBITDA: 16.61; 18.41

Share statisticsIndustry

Shares Outstanding: 517M; 43M
Shares Change (YoY): 0.68%; 3.32%
Float: 514M; 37M
Shares Held by Insiders: 0.58%; 10.5%
Shares Held by Institutions: 107.6%; 60.5%

Short sellingIndustry

Short Interest: 24M; –
Short Interest Change: -0.38%; -2.57%
Short % of Float: 4.60%; 5.11%
Short % of Shares Outstanding: 4.58%; 3.98%
Days to Cover: 3.00; 3.94

Stock price statisticsIndustry

52-Week High: $30.00; –
52-Week Low: $15.73; –
20-Day Moving Average: $25.28; –
50-Day Moving Average: $24.54; –
200-Day Moving Average: $21.64; –
Average True Range (14): $0.98; –
Price Change (1 Week): 0.08%; 0.99%
Price Change (1 Month): 0.19%; -3.52%
Price Change (3 Months): -0.39%; -7.86%
Price Change (6 Months): 49.2%; -1.12%
Price Change (YTD): 35.1%; -2.92%
Price Change (1 Year): 38.0%; -1.37%
Price Change (3 Years): -24.9%; 3.24%
Price Change (5 Years): -67.5%; -50.4%
Price Change (10 Years): -42.7%; 58.9%
Average Volume (10 Days): 7M; –
Average Volume (20 Days): 8M; –
Average Volume (90 Days): 7M; –
Relative Volume: 0.67; 0.76
Relative Strength Index (14): 54.3; 46.7
Volatility (1 Year): 42.1%; 64.2%
Beta (5 Years): 0.79; 1.04

MarginsIndustry

Gross Margin: 30.1%; 55.9%
Operating Margin: -1.90%; -5.12%
Pretax Margin: -1.61%; -2.32%
Profit Margin: -6.23%; -9.29%
EBITDA Margin: 6.32%; -2.52%

Returns on capitalIndustry

Return on Equity (ROE): -10.5%; -17.3%
Return on Assets (ROA): -3.57%; -12.3%
Return on Invested Capital (ROIC): -3.00%; -2.83%
Return on Capital Employed (ROCE): -1.42%; -8.13%

Financial positionIndustry

Current Ratio: 1.79; 2.49
Quick Ratio: 0.99; 1.53
Debt / Equity: 0.13; 0.42
Debt / EBITDA: 1.15; 2.23
Net Debt / EBITDA: -1.54; 1.49
Interest Coverage: -0.75; -1.63

GrowthIndustry

Revenue Growth (YoY): 5.33%; 9.42%
Revenue Growth (3Y CAGR): 3.79%; 7.08%
Revenue Growth (5Y CAGR): -0.75%; 11.8%

EfficiencyIndustry

Asset Turnover: 0.57; 0.59
Inventory Turnover: 3.41; 2.20
Revenue Per Employee: $309.63K; $331.99K
Profits Per Employee: -$19.28K; -$46.47K
Employee Count: 37,500; 193
WACC: 9.23%; 9.91%

Income statement (TTM)Industry

Revenue: $11.61B; $108.17M
Gross Profit: $3.49B; $62.29M
Operating Income: -$221.00M; -$3.72M
Pretax Income: -$187.00M; -$1.83M
Net Income: -$723.00M; -$6.19M
EBITDA: $734.00M; -$1.98M
EPS (Diluted): -$1.43; -$0.11

Balance sheetIndustry

Cash & Short-Term Investments: $1.98B; $38.97M
Total Debt: $844.00M; $96.00M
Net Cash (Debt): $1.13B; $3.95M
Net Cash Per Share: $2.19; $0.26
Equity (Book Value): $6.50B; $63.80M
Book Value Per Share: $12.57; $3.26
Tangible Book Value: -$2.30B; $11.61M
Working Capital: $3.02B; $57.32M

Cash flow (TTM)Industry

Operating Cash Flow: $1.64B; -$483.87K

Dividends and yieldsIndustry

Earnings Yield: -5.41%; -4.76%
Dividend Yield: 2.01%; 0.79%
Shareholder Yield: 2.01%; 1.12%
Dividend Per Share: $0.52; $0.72
Dividend Growth (YoY): -50.0%; 4.88%
Years of Dividend Growth: 0; 0

Taxes and interestIndustry

Interest Expense: $293.00M; $5.40M
Income Tax: $432.00M; $1.55M

Scores and fair valueIndustry

Altman Z-Score: 2.38; 2.47
Piotroski F-Score: 4; 5
Beneish M-Score: -2.67; -2.64

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	BAX	S&P 500	Difference	BAX per year	S&P 500 per year
1 month	+3.7%	-3.0%	+6.7 pts
3 months	-4.5%	-2.8%	−1.8 pts
Year to date	+35.2%	+11.5%	+23.8 pts
1 year	+38.3%	+13.5%	+24.8 pts
3 years	-19.0%	+77.7%	−96.7 pts	-6.8%	+21.1%
5 years	-64.2%	+72.6%	−136.8 pts	-18.6%	+11.5%
10 years	-35.7%	+308.2%	−343.9 pts	-4.3%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

24M BAX shares were sold short on Oct 30, 2026, down 0.4% from the previous report, or 4.60% of the shares available to trade. At recent volumes it would take 3.0 days to buy them back. Over the last 20 sessions, 60.3% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	23,674,982	-0.4%	7,900,719	3.0
Oct 15, 2026	23,765,665	-2.5%	5,674,639	4.2
Sep 30, 2026	24,366,869	+4.9%	8,190,013	3.0
Sep 15, 2026	23,227,313	-0.3%	5,185,542	4.5
Aug 31, 2026	23,293,667	-2.6%	4,667,401	5.0
Aug 14, 2026	23,914,369	-26.8%	7,950,123	3.0
Jul 31, 2026	32,667,256	-11.3%	7,531,769	4.3
Jul 15, 2026	36,839,907	-4.5%	5,647,222	6.5
Jun 30, 2026	38,589,003	-7.4%	7,059,803	5.5
Jun 15, 2026	41,665,129	-1.8%	6,942,537	6.0
May 29, 2026	42,412,694	+5.1%	6,894,441	6.2
May 15, 2026	40,350,973	+15.0%	7,208,384	5.6

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Baxter International's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on May 31, 2001
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BAX.

Compare: BAX vs SOLV · BAX vs BDX · BAX vs BSX · BAX vs RMD · BAX vs TFX

Revenue growth5.3% · median 9.0%

Gross margin30.1% · median 58.3%

Operating margin-1.9% · median 10.7%

Net margin-6.2% · median 8.8%

Company	Revenue	Growth
BDX	$23.25B	+17.4%
BSX	$21.07B	+8.9%
BAX	$11.61B	+5.3%
SOLV	$8.16B	-2.8%
RMD	$5.73B	+9.0%
TFX	$2.26B	+20.9%

Company

Next earnings (est.): Feb 11, 2027, before open
Exchange: NYSE
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 37,500
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 10456

Advertisement
300 × 250

See a number that looks wrong?